191 related articles for article (PubMed ID: 38636338)
1. Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy.
Zhou Q; Tu X; Hou X; Yu J; Zhao F; Huang J; Kloeber J; Olson A; Gao M; Luo K; Zhu S; Wu Z; Zhang Y; Sun C; Zeng X; Schoolmeester KJ; Weroha JS; Hu X; Jiang Y; Wang L; Mutter RW; Lou Z
Drug Resist Updat; 2024 May; 74():101085. PubMed ID: 38636338
[TBL] [Abstract][Full Text] [Related]
2. Syk-dependent alternative homologous recombination activation promotes cancer resistance to DNA targeted therapy.
Zhou Q; Tu X; Hou X; Yu J; Zhao F; Huang J; Kloeber J; Olson A; Gao M; Luo K; Zhu S; Wu Z; Zhang Y; Sun C; Zeng X; Schoolmeester K; Weroha J; Wang L; Mutter R; Lou Z
Res Sq; 2023 Jun; ():. PubMed ID: 37333340
[TBL] [Abstract][Full Text] [Related]
3. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
4. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Xu G; Chapman JR; Brandsma I; Yuan J; Mistrik M; Bouwman P; Bartkova J; Gogola E; Warmerdam D; Barazas M; Jaspers JE; Watanabe K; Pieterse M; Kersbergen A; Sol W; Celie PHN; Schouten PC; van den Broek B; Salman A; Nieuwland M; de Rink I; de Ronde J; Jalink K; Boulton SJ; Chen J; van Gent DC; Bartek J; Jonkers J; Borst P; Rottenberg S
Nature; 2015 May; 521(7553):541-544. PubMed ID: 25799992
[TBL] [Abstract][Full Text] [Related]
5. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
[TBL] [Abstract][Full Text] [Related]
6. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
8. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Noordermeer SM; van Attikum H
Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
[TBL] [Abstract][Full Text] [Related]
11. LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.
Wang YS; Chen J; Cui F; Wang H; Wang S; Hang W; Zeng Q; Quan CS; Zhai YX; Wang JW; Shen XF; Jian YP; Zhao RX; Werle KD; Cui R; Liang J; Li YL; Xu ZX
Oncotarget; 2016 Nov; 7(45):73389-73401. PubMed ID: 27705915
[TBL] [Abstract][Full Text] [Related]
12. The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair.
Wang H; Shi LZ; Wong CC; Han X; Hwang PY; Truong LN; Zhu Q; Shao Z; Chen DJ; Berns MW; Yates JR; Chen L; Wu X
PLoS Genet; 2013; 9(2):e1003277. PubMed ID: 23468639
[TBL] [Abstract][Full Text] [Related]
13. Ataxia telangiectasia mutated (ATM) is dispensable for endonuclease I-SceI-induced homologous recombination in mouse embryonic stem cells.
Rass E; Chandramouly G; Zha S; Alt FW; Xie A
J Biol Chem; 2013 Mar; 288(10):7086-95. PubMed ID: 23355489
[TBL] [Abstract][Full Text] [Related]
14. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
[TBL] [Abstract][Full Text] [Related]
16. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
17. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
19. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]